TikoMed develops ILB®, a novel small‑molecule drug candidate that activates the body’s own repair mechanisms to reduce cell‑death triggers and protect tissue in progressive diseases. The platform targets underlying pathological processes in neurodegenerative and cardiovascular conditions, and is being advanced through preclinical validation and early clinical studies with pharmaceutical and academic partners.
Funding
$5.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurodegenerative and other progressive diseases often lack therapies that can halt or reverse cellular damage, leading to continual decline and limited treatment options for patients.
Solution
TikoMed has developed ILB®, a novel small‑molecule drug candidate that activates the body’s intrinsic repair pathways. By modulating mechanisms that trigger cell death, ILB aims to reduce neurotoxic cascades and protect tissue even when disease‑related stressors persist. The approach targets underlying pathological processes rather than symptomatic relief, offering the potential to improve outcomes in conditions that are currently untreatable. Preclinical data show neuroprotective activity, and the company is advancing ILB into clinical studies for amyotrophic lateral sclerosis, myocardial infarction, and other progressive disorders. TikoMed leverages its combined expertise in drug development, business strategy, and partnership networks to move ILB from laboratory research to commercial availability.
Target Audience
Primary customers are pharmaceutical partners, biotech companies, and academic research institutions seeking novel disease‑modifying agents for neurodegenerative and cardiovascular indications.
Features
- Small‑molecule ILB® designed to stimulate endogenous cellular repair mechanisms
- Dual action: reduces upstream triggers of cell death and provides protection despite ongoing pathological stress
- Broad applicability across neurodegenerative, cardiovascular, and other progressive disease indications
- Preclinical validation of neuroprotective efficacy and safety profile
- Structured partnership model with academic and clinical institutions to accelerate clinical testing